• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

62.78 +1.71 (+2.80%)
Streaming Delayed Price Updated: 1:52 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 234,383
Open 60.43
Bid (Size) 62.76 (100)
Ask (Size) 63.62 (200)
Prev. Close 61.07
Today's Range 60.19 - 63.83
52wk Range 22.50 - 105.00
Shares Outstanding 14,157,941
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
November 14, 2025
 
Via Benzinga

Performance

YTD
-4.9%
-4.9%
1 Month
-17.9%
-17.9%
3 Month
-36.3%
-36.3%
6 Month
+63.6%
+63.6%
1 Year
+166.0%
+166.0%

More News

Read More
News headline image
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
November 13, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
November 09, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
October 15, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
October 13, 2025
Via Benzinga
News headline image
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗
September 25, 2025
Via Benzinga
News headline image
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
September 23, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
September 23, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout ↗
September 15, 2025
Via Investor's Business Daily
News headline image
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
September 14, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
September 03, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
August 12, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
June 23, 2025
Via Benzinga
News headline image
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
June 11, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
June 03, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
May 13, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
May 07, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
April 29, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
March 31, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
March 21, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
December 20, 2024
Via Benzinga
News headline image
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
December 20, 2024
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
December 05, 2024
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
December 03, 2024
From Monopar Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Monopar Therapeutics Inc. - Common Stock publicly traded?
Yes, Monopar Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Monopar Therapeutics Inc. - Common Stock trade on?
Monopar Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Monopar Therapeutics Inc. - Common Stock?
The ticker symbol for Monopar Therapeutics Inc. - Common Stock is MNPR on the Nasdaq Stock Market
What is the current price of Monopar Therapeutics Inc. - Common Stock?
The current price of Monopar Therapeutics Inc. - Common Stock is 62.78
When was Monopar Therapeutics Inc. - Common Stock last traded?
The last trade of Monopar Therapeutics Inc. - Common Stock was at 01/07/26 01:52 PM ET
What is the market capitalization of Monopar Therapeutics Inc. - Common Stock?
The market capitalization of Monopar Therapeutics Inc. - Common Stock is 888.84M
How many shares of Monopar Therapeutics Inc. - Common Stock are outstanding?
Monopar Therapeutics Inc. - Common Stock has 889M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap